MedTrace Logo

Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)

NCT04542382 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-03-30

No results posted yet for this study

Summary

This is an open-label, non-randomized, fixed-sequence study. Subjects will undergo a rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast Cancer Resistance Protein (BCRP).

Conditions

  • Healthy Volunteers

Interventions

DRUG

Rosuvastatin

Rosuvastatin will be administered as follows: Day 1: single dose of 10 mg Rosuvastatin tablet.

DRUG

Rosuvastatin (Inhibitor arm)

Rosuvastatin will be administered as follows: Day 8: single dose of 10 mg Rosuvastatin tablet.

DRUG

Eltrombopag

Eltrombopag will be administered as follows: Day 8: single dose of 75 mg Eltrombopag tablet.

Sponsors & Collaborators

Principal Investigators

  • Kathleen M Giacomini, Ph.D. · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-28
Primary Completion
2023-08-11
Completion
2023-08-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542382 on ClinicalTrials.gov